SG11201909584QA - Triterpene saponin analogues - Google Patents
Triterpene saponin analoguesInfo
- Publication number
- SG11201909584QA SG11201909584QA SG11201909584QA SG11201909584QA SG 11201909584Q A SG11201909584Q A SG 11201909584QA SG 11201909584Q A SG11201909584Q A SG 11201909584QA SG 11201909584Q A SG11201909584Q A SG 11201909584QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- new york
- street
- pct
- strain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/256—Polyterpene radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762489556P | 2017-04-25 | 2017-04-25 | |
PCT/US2018/029314 WO2018200645A1 (en) | 2017-04-25 | 2018-04-25 | Triterpene saponin analogues |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909584QA true SG11201909584QA (en) | 2019-11-28 |
Family
ID=63918682
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909584Q SG11201909584QA (en) | 2017-04-25 | 2018-04-25 | Triterpene saponin analogues |
SG10202108075YA SG10202108075YA (en) | 2017-04-25 | 2018-04-25 | Triterpene saponin analogues |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202108075YA SG10202108075YA (en) | 2017-04-25 | 2018-04-25 | Triterpene saponin analogues |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210283248A1 (de) |
EP (1) | EP3618836A4 (de) |
JP (2) | JP2020517679A (de) |
KR (1) | KR20190137827A (de) |
CN (1) | CN110582282A (de) |
AU (1) | AU2018258070A1 (de) |
CA (1) | CA3061205A1 (de) |
CL (1) | CL2019003064A1 (de) |
IL (2) | IL292991A (de) |
SG (2) | SG11201909584QA (de) |
WO (1) | WO2018200645A1 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018350887A1 (en) * | 2017-10-16 | 2020-03-05 | Adjuvance Technologies, Inc. | Triterpene saponin analogues |
GB2592769B (en) * | 2020-03-01 | 2022-05-04 | Valneva Austria Gmbh | CpG-Adjuvanted SARS-CoV-2 virus vaccine |
WO2023056089A1 (en) | 2021-10-03 | 2023-04-06 | Eisai R&D Management Co., Ltd. | Immunological adjuvant formulations comprising tlr4 agonist e6020 |
EP4190359A1 (de) | 2021-12-03 | 2023-06-07 | Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE | Saponinbasierte adjuvantien und impfstoffe |
WO2023139145A1 (en) | 2022-01-19 | 2023-07-27 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | Saponin-based adjuvants and vaccines |
CN117244053B (zh) * | 2023-10-16 | 2024-04-26 | 国药中生生物技术研究院有限公司 | 具有常春藤皂苷元-O-Ara结构的化合物的佐剂用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5583112A (en) * | 1987-05-29 | 1996-12-10 | Cambridge Biotech Corporation | Saponin-antigen conjugates and the use thereof |
UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US8029795B2 (en) * | 1999-12-30 | 2011-10-04 | Gwathmey, Inc. | Targeted iron chelator delivery system |
GB0401239D0 (en) * | 2004-01-21 | 2004-02-25 | Molecularnature Ltd | Adjuvant compositions |
GB0504436D0 (en) * | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
KR101333279B1 (ko) * | 2006-10-06 | 2013-11-27 | 에스씨아이엘 테크놀로지 게엠베하 | 약학적 응용을 위한 건조된 재구성 소포 형성 |
JP2011507816A (ja) * | 2007-12-21 | 2011-03-10 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | マラリア用ワクチン |
AU2009233757B2 (en) * | 2008-04-08 | 2015-05-07 | Sloan-Kettering Institute For Cancer Research | Triterpene saponins, methods of synthesis, and uses thereof |
ES2678694T3 (es) * | 2008-04-16 | 2018-08-16 | Glaxosmithkline Biologicals Sa | Vacuna |
CN107029222A (zh) * | 2010-05-26 | 2017-08-11 | 西莱克塔生物科技公司 | 合成纳米载体联合疫苗 |
US20130309273A1 (en) * | 2012-05-17 | 2013-11-21 | Kimberly Hassett | Thermostable Vaccine Compositions and Methods of Preparing Same |
CN108778289B (zh) * | 2015-11-06 | 2020-11-17 | 佐剂技术公司 | 三萜皂苷类似物 |
JP2020516657A (ja) * | 2017-04-13 | 2020-06-11 | アジュバンス・テクノロジーズ・インコーポレーテッド | トリテルペンサポニン合成、中間体及びアジュバントの組み合わせ |
-
2018
- 2018-04-25 US US16/608,296 patent/US20210283248A1/en active Pending
- 2018-04-25 WO PCT/US2018/029314 patent/WO2018200645A1/en unknown
- 2018-04-25 JP JP2019557802A patent/JP2020517679A/ja active Pending
- 2018-04-25 SG SG11201909584Q patent/SG11201909584QA/en unknown
- 2018-04-25 AU AU2018258070A patent/AU2018258070A1/en not_active Abandoned
- 2018-04-25 CN CN201880027682.1A patent/CN110582282A/zh active Pending
- 2018-04-25 SG SG10202108075YA patent/SG10202108075YA/en unknown
- 2018-04-25 IL IL292991A patent/IL292991A/en unknown
- 2018-04-25 KR KR1020197031159A patent/KR20190137827A/ko not_active Application Discontinuation
- 2018-04-25 EP EP18791428.8A patent/EP3618836A4/de active Pending
- 2018-04-25 CA CA3061205A patent/CA3061205A1/en active Pending
-
2019
- 2019-10-24 IL IL270182A patent/IL270182B/en unknown
- 2019-10-25 CL CL2019003064A patent/CL2019003064A1/es unknown
-
2022
- 2022-09-28 JP JP2022154385A patent/JP2022191284A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SG10202108075YA (en) | 2021-09-29 |
EP3618836A4 (de) | 2021-01-13 |
WO2018200645A1 (en) | 2018-11-01 |
US20210283248A1 (en) | 2021-09-16 |
IL292991A (en) | 2022-07-01 |
CN110582282A (zh) | 2019-12-17 |
CL2019003064A1 (es) | 2020-03-13 |
KR20190137827A (ko) | 2019-12-11 |
AU2018258070A1 (en) | 2019-10-24 |
CA3061205A1 (en) | 2018-11-01 |
JP2020517679A (ja) | 2020-06-18 |
JP2022191284A (ja) | 2022-12-27 |
IL270182B (en) | 2022-06-01 |
EP3618836A1 (de) | 2020-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909584QA (en) | Triterpene saponin analogues | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
SG11201902938TA (en) | Compounds, devices, and uses thereof | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201909311TA (en) | Triterpene saponin synthesis, intermediates and adjuvant combinations | |
SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
SG11201907023UA (en) | Method of reducing neutropenia | |
SG11201806845VA (en) | Moisturizing compositions and uses thereof | |
SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same |